⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
FBLG News
FibroBiologics, Inc. Common Stock
Form 8-K
sec.gov
FBLG
Form 8-K
sec.gov
FBLG
FibroBiologics Appoints Kathleen "Kate" Rubins, Ph.D. to Board of Directors
prnewswire.com
FBLG
FibroBiologics Completes Manufacturing of Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
prnewswire.com
FBLG
Form 8-K
sec.gov
FBLG
FibroBiologics Announces Closing of up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
prnewswire.com
FBLG
Form 8-K
sec.gov
FBLG
FibroBiologics Receives Notice of Allowance for U.S. Patent Covering Topical Fibroblast Spheroid Therapy for Wound Healing
globenewswire.com
FBLG
FibroBiologics Advances Patient Dosing for Phase 1/2 Clinical Trial of CYWC628 for the Treatment of Diabetic Foot Ulcers
globenewswire.com
FBLG
FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers
globenewswire.com
FBLG